Skip to content
Menu

Wave Life Sciences Anticipates $12M Milestone Payment From GSK In Q4

Benzinga Newsdesk 3 weeks ago

News

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the third quarter

Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

  • Cash, cash equivalents, and marketable securities were $431.0 million as of September 30, 2026, which did not include the $12 million milestone from GSK that will be received in the fourth quarter of 2026. Wave expects that its current cash, cash equivalents, and marketable securities will be sufficient to fund operations into the third quarter of 2028. Potential future milestone and other payments to Wave under its GSK collaboration are not included in its cash runway.

Read at benzinga.com